US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Renaissance Technologies Holdings

1,668.99

-40.4440-2.37%

Number of Gainers:24

Number of Losers:71

Number of Flat:1

PE:- -

High:1,706.57

Open:1,706.57

Low:1,651.25

Close:1,709.44

Loading ...

Bausch (BHC) Moves 13.3% Higher: Will This Strength Last?

Jim Cramer Calls Colgate-Palmolive Company (CL) a Recession-Resistant Winner

Gilead ASCENT-04 data a ‘welcome surprise,’ says Oppenheimer

Netflix Inc : Macquarie Raises Target Price to $1,200 From $1,150

THOMSON REUTERS

Market Chatter: European Commission President Asks X, Meta, TikTok to Comply With EU Digital Rulebook

MT Newswires Live

Cytokinetics reiterated as top pick at H.C. Wainwright, Camzyos updates positive

Johnson & Johnson announces new data from oncology pipeline at AUA meeting

Unusually active option classes on open April 21st

Netflix Shares up 3.3% After Q1 Results Beat

THOMSON REUTERS

Brokers Suggest Investing in Palo Alto (PANW): Read This Before Placing a Bet

Netflix Beats Estimates, Eyes Ad Growth as Q2 Outlook Impresses

Sanofi & Regeneron's Dupixent Receives FDA Nod for Urticaria

Apple may have a key problem bringing back manufacturing to beat Trump tariffs, former Intel CEO warns

Notable open interest changes for April 21st

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Tariffs Weigh on Investor Sentiment, Driving Premarket Losses for US Equity Futures

MT Newswires Live

LLY Stock Up as Oral GLP-1 Pill Meets Goals in First Phase III Study

BRIEF-Gilead Reports Positive Topline Results From Phase 3 Ascent-04/Keynote-D19 Study

Gilead: Positive Topline Results From Phase 3 Ascent-04/Keynote-D19 Study

THOMSON REUTERS

Gilead: Overall Survival (Os), Key Secondary Endpoint, Wasn't Mature at Time of Pfs Primary Analysis

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK4532/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4532","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4532\",,,,,undefined,":{"symbol":"BK4532","market":"US","secType":"PLATE","nameCN":"Renaissance Technologies Holdings","latestPrice":1668.9934,"timestamp":1745265599999,"preClose":1709.4374,"halted":0,"volume":986316877,"delay":0,"changeRate":-0.023659,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":-40.44397,"latestTime":"04-21 16:00:00 EDT","open":1706.567,"high":1706.567,"low":1651.2467,"amount":107533974009.5662,"amplitude":0.032362,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1745328600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":7.646899,"peRate":27.342263,"turnoverRate":0.007661,"increases":24,"decrements":71,"flats":1,"marketCap":18646353158056,"floatMarketCap":17401452628376},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4532\",,,,,undefined,":{"symbol":"BK4532","high":1706.567,"amplitude":0.032362,"preClose":1709.4374,"low":1651.2467,"pbRate":"7.646899","latestPrice":1668.9934,"volume":986316877,"delay":0,"open":1706.567,"prevYearClose":2026.1482,"prevWeekClose":1709.4374,"prevMonthClose":1820.2863,"prevQuarterClose":1820.2863,"fiveDayClose":1777.517,"twentyDayClose":1872.4913,"sixtyDayClose":2095.5317,"secType":"PLATE","market":"US","turnoverRate":0.007661,"peRate":27.342263,"marketCap":18646353158056,"floatMarketCap":17401452628376,"timestamp":1745265599999,"nameCN":"Renaissance Technologies Holdings"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4532\",,,,undefined,":{"bkCode":"BK4532","up":24,"down":71,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4532\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2529875213","title":"Bausch (BHC) Moves 13.3% Higher: Will This Strength Last?","url":"https://stock-news.laohu8.com/highlight/detail?id=2529875213","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529875213?lang=en_us&edition=fundamental","pubTime":"2025-04-21 22:23","pubTimestamp":1745245380,"startTime":"0","endTime":"0","summary":"Bausch Health BHC shares soared 13.3% in the last trading session to close at $5.10. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 35.7% loss over the past four weeks.Shares gained a district court in the United States granted summary judgment in favor of the company, its gastroenterology business Salix Pharmaceuticals and Teva Pharmaceuticals against Norwich which is looking to get its generic version of Xifaxan approved.This drugmaker is expected to post quarterly earnings of $1.46 per share in its upcoming report, which represents a year-over-year change of +147.5%. Revenues are expected to be $2.27 billion, up 5.5% from the year-ago quarter.Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.Bausch Health Cos Inc.  : ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bausch-bhc-moves-13-3-142300853.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4557","BHC","RDY","BK4596","LU0348744763.USD","BK4007","BK4532","BK4523"],"gpt_icon":0},{"id":"2529738394","title":"Jim Cramer Calls Colgate-Palmolive Company (CL) a Recession-Resistant Winner","url":"https://stock-news.laohu8.com/highlight/detail?id=2529738394","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529738394?lang=en_us&edition=fundamental","pubTime":"2025-04-21 22:15","pubTimestamp":1745244935,"startTime":"0","endTime":"0","summary":"On Thursday, Jim Cramer, the host of Mad Money, walked viewers through what he described as an important week ahead for Wall Street, with earnings season hitting full stride and a flood of quarterly reports expected from companies spanning multiple sectors.“The fact is the president wants lower interest rates to help offset the pain from higher prices that gonna be caused by the tariffs, but higher prices represent inflation.”READ ALSO:12 Stocks on Jim Cramer’s Radar RecentlyandJim Cramer Discussed These 12 Stocks Recently.“The Federal Reserve never cuts rates when inflation’s out of control,” Cramer emphasized and added that it may very well become the case if tariffs continue to drive up costs. He made it clear that he respects Fed Chair Jerome Powell as he described him as a capable public servant who, in Cramer’s words, has “generally done a good job.” Still, he acknowledged Powell’s difficult position as he said the Fed chair is “stuck between a rock and a hard place.” He added:","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/jim-cramer-calls-colgate-palmolive-141535651.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1585245621.USD","LU0266013472.USD","US10Y.BOND","LU2360032135.SGD","BK4585","LU0985320562.USD","BK4018","LU0323591593.USD","LU0731783394.SGD","BK4588","LU1150488218.USD","CL","US6M.BOND","LU1599440770.SGD","LU1236620834.HKD","BK4532","LU2125154935.USD","US30Y.BOND","US12M.BOND","LU1675838814.USD","LU1941712348.USD","LU2463526074.USD","LU1430594728.SGD","LU2125154778.USD","LU1571399168.USD","LU1236620750.USD","US5Y.BOND","LU1941712264.USD","SG9999001440.SGD","US3Y.BOND","US7Y.BOND","US2Y.BOND","LU1150488135.SGD","BK4533","BK4504","LU2108987350.USD"],"gpt_icon":0},{"id":"2529800281","title":"Gilead ASCENT-04 data a ‘welcome surprise,’ says Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2529800281","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529800281?lang=en_us&edition=fundamental","pubTime":"2025-04-21 22:15","pubTimestamp":1745244927,"startTime":"0","endTime":"0","summary":"Oppenheimer says Gilead (GILD) provided a “welcome surprise” this morning with ASCENT-04 hitting its primary endpoint. The firm was not expecting t...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gilead-ascent-04-data-a-welcome-surprise-says-oppenheimer?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gilead-ascent-04-data-a-welcome-surprise-says-oppenheimer?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0234570918.USD","LU0889565916.HKD","IE00BZ1G4Q59.USD","GILD","BK4568","LU1066053197.SGD","LU1585245621.USD","IE00B19Z3581.USD","LU2468319806.SGD","LU0058720904.USD","IE00BKVL7J92.USD","LU1571399168.USD","IE00B19Z3B42.SGD","LU0320765992.SGD","BK4139","IE00B3T34201.USD","LU0109394709.USD","BK4583","LU1066051498.USD","OPY","LU2087621335.USD","BK4532","BK4550","IE0002270589.USD","BK4588","LU0289739699.SGD","BK4566","BK4578","LU2089984988.USD","BK4585","IE00B7SZLL34.SGD","IE00BSNM7G36.USD","LU1430594728.SGD","BK4127","LU1839511570.USD"],"gpt_icon":0},{"id":"2529014807","title":"Netflix Inc : Macquarie Raises Target Price to $1,200 From $1,150","url":"https://stock-news.laohu8.com/highlight/detail?id=2529014807","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529014807?lang=en_us&edition=fundamental","pubTime":"2025-04-21 22:07","pubTimestamp":1745244462,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250421:nFWN3QZ1OF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00BQXX3F31.USD","LU2237957811.SGD","SGXZ23171101.USD","LU2362540622.SGD","SG9999004303.SGD","LU0642271901.SGD","LU0868494708.USD","LU1823568750.SGD","BK4524","LU1035775433.USD","BK4585","LU0109391861.USD","LU0942090050.USD","BK4581","LU1064131342.USD","BK4588","LU0215105999.USD","LU0708995401.HKD","LU1046421795.USD","BK4566","LU1429558221.USD","LU1435385759.SGD","BK4534","LU2357305700.SGD","BK4598","LU0106261372.USD","IE00BQXX3D17.EUR","LU2362541273.HKD","LU0256863811.USD","LU2326559502.SGD","LU1720051017.SGD","LU2108987350.USD","LU2237957902.USD","NFLX","IE00B19Z8W00.USD","BK4527","SGXZ51526630.SGD","LU2362541513.USD","IE00B19Z9505.USD","LU1988902786.USD","BK4532","LU1069344957.HKD","LU2552382215.SGD","LU1267930730.SGD","LU0256863902.USD","LU0786609619.USD","LU1814569148.SGD","LU0082616367.USD","LU2552382058.USD"],"gpt_icon":0},{"id":"2529077268","title":"Market Chatter: European Commission President Asks X, Meta, TikTok to Comply With EU Digital Rulebook","url":"https://stock-news.laohu8.com/highlight/detail?id=2529077268","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529077268?lang=en_us&edition=fundamental","pubTime":"2025-04-21 22:05","pubTimestamp":1745244350,"startTime":"0","endTime":"0","summary":"European Commission President Ursula von der Leyen told Politico that companies like X, Meta , Apple  and TikTok should know the EU is ready to enforce its digital rules no matter who is in charge of these firms or where they're located.\"The rules voted by our co-legislators must be enforced,\" von der Leyen told Politico. \"That's why we've opened cases against TikTok, X, Apple, Meta just to name a few. We apply the rules fairly, proportionally, and without bias. We don't care where a company's from and who's running it. We care about protecting people.\"Politico reported that US Vice President JD Vance has criticized EU rules like the Digital Services Act, which targets content, or the bloc's AI Act.X, Meta, Apple and TikTok didn't immediately respond to a request for comment by MT Newswires.Price: 484.23, Change: -17.26, Percent Change: -3.44","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0788109477.HKD","LU2063271972.USD","IE00BLSP4452.SGD","LU2065169927.USD","LU0957808578.USD","IE0002270589.USD","LU0320765489.SGD","LU0786609619.USD","LU1791710400.SGD","LU1035775433.USD","LU1564329461.SGD","MACW.SI","META","SG9999014542.SGD","LU0345769128.USD","LU1046421795.USD","LU0109392836.USD","LU2065171402.SGD","LU0289739343.SGD","LU0251132253.USD","LU1914381329.SGD","LU0061475181.USD","IE00B19Z9505.USD","LU0942090050.USD","IE00B5949003.HKD","LU0708995401.HKD","LU2360032135.SGD","LU0476273544.USD","IE00B7KXQ091.USD","IE00BMPRXN33.USD","LU1235294995.USD","LU1244550221.USD","LU2764263203.CNY","SG9999002224.SGD","LU0545039389.USD","LU0157215616.USD","IE0005OL40V9.USD","LU1066051225.USD","LU1697837992.HKD","IE00BKVL7J92.USD","BK4532","LU1153585028.USD","LU0642271901.SGD","LU2168564222.USD","LU2286300806.USD","LU0965509010.AUD","IE00B19Z8W00.USD","LU2430703178.SGD"],"gpt_icon":1},{"id":"2529580044","title":"Cytokinetics reiterated as top pick at H.C. Wainwright, Camzyos updates positive","url":"https://stock-news.laohu8.com/highlight/detail?id=2529580044","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529580044?lang=en_us&edition=fundamental","pubTime":"2025-04-21 22:01","pubTimestamp":1745244085,"startTime":"0","endTime":"0","summary":"Recent label updates for Bristol Myers’ (BMY) Camzyos should read positively for obstructive hypertrophic cardiomyopathy patients and physicians, a...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cytokinetics-reiterated-as-top-pick-at-h-c-wainwright-camzyos-updates-positive?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cytokinetics-reiterated-as-top-pick-at-h-c-wainwright-camzyos-updates-positive?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0985481810.HKD","LU1032466523.USD","BK4588","LU0456855351.SGD","LU0321505439.SGD","LU1670710588.SGD","LU0237698245.USD","LU0868494617.USD","LU1571399168.USD","LU1868837300.USD","LU0225771236.USD","IE00B2B36J28.USD","BK4585","LU1093756168.USD","LU2242652126.USD","LU1323610961.USD","BMY","LU1585245621.USD","BK4581","LU1868836591.USD","IE00BJT1NW94.SGD","LU0061475181.USD","IE00BFTCPJ56.SGD","CYTK","LU0306806265.USD","LU0306807586.USD","LU1989771016.USD","LU2125154935.USD","LU0321505868.SGD","LU2360032135.SGD","IE0002141913.USD","BK4534","LU1718418525.SGD","IE00BFXG1179.USD","LU1074936037.SGD","LU1670711123.USD","LU1430594728.SGD","LU1670710661.SGD","LU1291159041.SGD","BK4007","LU1093756325.SGD","BK4532","LU1868836914.USD","LU1670711040.USD","LU0882574055.USD","IE00BJJMRZ35.SGD","LU2125154778.USD","LU1868836757.USD","BK4505","LU0096364046.USD"],"gpt_icon":0},{"id":"2529807518","title":"Johnson & Johnson announces new data from oncology pipeline at AUA meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2529807518","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529807518?lang=en_us&edition=fundamental","pubTime":"2025-04-21 21:56","pubTimestamp":1745243807,"startTime":"0","endTime":"0","summary":"Johnson & Johnson announced that new data from its oncology pipeline will be presented at the American Urological Association 2025 Annual Meeting, ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/johnson-johnson-announces-new-data-from-oncology-pipeline-at-aua-meeting?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/johnson-johnson-announces-new-data-from-oncology-pipeline-at-aua-meeting?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BGHQF631.EUR","LU1221951129.SGD","LU1718418525.SGD","LU1032466523.USD","SG9999002224.SGD","LU1929549753.HKD","LU1261432733.SGD","LU2112291526.USD","LU0320765646.SGD","LU1894683348.USD","LU2347655156.SGD","LU1244550577.SGD","IE00BJJMRZ35.SGD","LU0889566641.SGD","BK4588","LU0345769631.USD","IE00B3T34201.USD","LU0792757196.USD","LU1162221912.USD","LU0345770308.USD","LU0098860793.USD","LU1244550221.USD","IE00B2B36J28.USD","IE00BVYPNV92.GBP","LU0985320562.USD","LU1674673691.USD","LU0234572021.USD","LU0345769128.USD","LU1585245621.USD","LU2129689514.USD","LU1066053197.SGD","LU1280957306.USD","BK4532","IE00BDGV0183.EUR","SG9999001440.SGD","BK4568","LU1066051225.USD","IE00B42XCP33.USD","IE00BLSP4239.USD","IE00BN8TJ469.HKD","LU0234570918.USD","IE00B19Z3B42.SGD","LU1074936037.SGD","LU2133065610.SGD","LU2430703095.HKD","LU1430594728.SGD","LU0203345920.USD","LU0912757837.SGD","JNJ","LU0114720955.EUR"],"gpt_icon":0},{"id":"2529807567","title":"Unusually active option classes on open April 21st","url":"https://stock-news.laohu8.com/highlight/detail?id=2529807567","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529807567?lang=en_us&edition=fundamental","pubTime":"2025-04-21 21:40","pubTimestamp":1745242820,"startTime":"0","endTime":"0","summary":"Unusual total active option classes on open include: Mural Oncology PLC (MURA), General Electric (GE), Barrick Gold (GOLD), TeraWulf (WULF), AMC En...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/unusually-active-option-classes-on-open-april-21st-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/unusually-active-option-classes-on-open-april-21st-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AMC","BK4532","LU0075056555.USD","LU0055631609.USD","LU0345780521.USD","LU0788108826.HKD","LU0820561818.USD","BK4566","LU0820561909.HKD","LU0724618789.USD","BK4017","LU1366333091.USD","LU1261432733.SGD","LU2756315664.SGD","LU1988902786.USD","WULF","LU0345770308.USD","LU1366192091.USD","LU0354030511.USD","SG9999001143.SGD","GE","LU0157215616.USD","LU0345781412.USD","BK4108","LU1280957306.USD","LU1064131342.USD","LU0354030438.USD","LU0496367417.USD","BK4547","LU0640476718.USD","LU1223083913.SGD","LU0820562030.AUD","LU0345780281.USD","LU0943347566.SGD","LU2543165471.USD","LU1551013425.SGD","LU0630314457.HKD","LU1023059493.AUD","MURA","LU0498741890.SGD","LU1551013342.USD","LU0689472784.USD","BK4600","GOLD","LU0368265764.SGD","BK4501","BK4588","LU0330918003.SGD","LU1093756325.SGD","BK4570"],"gpt_icon":0},{"id":"2529046678","title":"Netflix Shares up 3.3% After Q1 Results Beat","url":"https://stock-news.laohu8.com/highlight/detail?id=2529046678","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529046678?lang=en_us&edition=fundamental","pubTime":"2025-04-21 21:31","pubTimestamp":1745242277,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250421:nL4N3QZ0TG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00B19Z8X17.USD","BK4548","LU1814569148.SGD","LU1988902786.USD","LU0079474960.USD","BK4598","LU0786609619.USD","LU2264538146.SGD","LU0256863902.USD","BK4108","IE00BQXX3D17.EUR","LU1046421795.USD","LU1435385759.SGD","BK4581","LU1548497426.USD","SGXZ51526630.SGD","LU0882574139.USD","LU1823568750.SGD","LU1720051108.HKD","LU1989764664.SGD","LU2362541273.HKD","LU0082616367.USD","LU0006306889.USD","SGXZ99366536.SGD","IE00B19Z8W00.USD","LU0672654240.SGD","LU0942090050.USD","LU2552382132.HKD","IE00BQXX3C00.GBP","LU2362541513.USD","BK4587","NFLX","LU2326559502.SGD","LU2552382215.SGD","IE00BKPKM429.USD","SGXZ81514606.USD","LU0106261372.USD","LU2108987350.USD","LU1720051017.SGD","SG9999004303.SGD","LU1429558221.USD","SGXZ23171101.USD","BK4532","LU1069344957.HKD","LU0719512351.SGD","LU0868494617.USD","LU1267930730.SGD","LU1316542783.SGD","IE00BQXX3F31.USD"],"gpt_icon":0},{"id":"2529389289","title":"Brokers Suggest Investing in Palo Alto (PANW): Read This Before Placing a Bet","url":"https://stock-news.laohu8.com/highlight/detail?id=2529389289","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529389289?lang=en_us&edition=fundamental","pubTime":"2025-04-21 21:30","pubTimestamp":1745242207,"startTime":"0","endTime":"0","summary":"When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed  analysts often influence a stock's price, but are they really important?Let's take a look at what these Wall Street heavyweights have to say about Palo Alto Networks  before we discuss the reliability of brokerage recommendations and how to use them to your advantage.Palo Alto currently has an average brokerage recommendation  of 1.63, on a scale of 1 to 5 , calculated based on the actual recommendations  made by 48 brokerage firms. An ABR of 1.63 approximates between Strong Buy and Buy.Of the 48 recommendations that derive the current ABR, 33 are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 68.8% and 4.2% of all recommendations.The vested interest of brokerage firms in a stock they cover often results in a strong positive bias of their analysts in rating it. Our research shows that for ever","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/brokers-suggest-investing-palo-alto-133007570.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4598","IE00B19Z9505.USD","LU1804176565.USD","LU1720051108.HKD","LU1720051017.SGD","BK4585","BK4581","IE00BMPRXR70.SGD","LU2125909759.SGD","LU1917777945.USD","LU1989764748.USD","LU1861215975.USD","LU1861220033.SGD","LU1169589451.USD","BK4110","IE00B19Z8W00.USD","BK4550","BK4532","LU2265009873.SGD","LU2125909916.SGD","ABR","LU2023250504.SGD","SG9999001424.SGD","LU1974910355.USD","LU1548497426.USD","LU2023250843.SGD","PANW","LU1169590202.USD","LU0348723411.USD","LU2106854487.HKD","BK4560","LU1923622291.USD","IE00BMPRXN33.USD","BK4097","LU0234570918.USD","LU2357305700.SGD","LU2286300806.USD","IE00B19Z8X17.USD","BK4588","LU1989764664.SGD"],"gpt_icon":0},{"id":"2529802899","title":"Netflix Beats Estimates, Eyes Ad Growth as Q2 Outlook Impresses","url":"https://stock-news.laohu8.com/highlight/detail?id=2529802899","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529802899?lang=en_us&edition=fundamental","pubTime":"2025-04-21 21:28","pubTimestamp":1745242087,"startTime":"0","endTime":"0","summary":"Netflix  shares rose about 1.95% at $992 as of 7:54:06 AM ET in pre?quarter results beat expectations across profit, revenue and margins.The company posted earnings per share of $6.61 under generally accepted accounting principles, beating estimates by $0.95. Revenue reached $10.54 billion, a 12.5% increase from a year earlier and $40 million ahead of projections. Operating income climbed to $3.3 billion, up 27% year over year, while the operating margin rose to 32%, slightly ahead of internal targets due to stronger-than-anticipated sales and delayed expenses.For the second quarter, Netflix anticipates 15% revenue growth , citing pricing changes and increased ad and membership revenue. The company expects a 33% operating margin, marking a 6-point gain from a year ago.Netflix reaffirmed its 2025 revenue guidance of $43.5 billion to $44.5 billion, near analyst consensus, and aims for a 29% operating margin. While foreign exchange shifts have been favorable recently, no major change has ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/netflix-beats-estimates-eyes-ad-132807282.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4108","LU0868494617.USD","LU0708995401.HKD","LU0106261372.USD","LU1316542783.SGD","LU0079474960.USD","LU1069344957.HKD","BK4507","IE00BQXX3C00.GBP","BK4598","LU0320765059.SGD","LU1988902786.USD","LU1989764664.SGD","LU0417517546.SGD","IE00BKPKM429.USD","BK4585","LU0719512351.SGD","LU1064131342.USD","LU2237957811.SGD","LU2552382058.USD","LU2552382215.SGD","BK4548","BK4587","LU2237957902.USD","SG9999004303.SGD","LU1267930730.SGD","LU1035775433.USD","LU0642271901.SGD","LU2362541273.HKD","BK4551","SGXZ81514606.USD","BK4566","SGXZ51526630.SGD","LU2326559502.SGD","LU1823568750.SGD","LU0672654240.SGD","LU2362540622.SGD","BK4532","IE00B19Z8X17.USD","LU0097036916.USD","NFLX","LU1429558221.USD","SGXZ23171101.USD","LU1435385759.SGD","LU0082616367.USD","SGXZ99366536.SGD","LU1046421795.USD","LU1548497426.USD","IE00BQXX3D17.EUR"],"gpt_icon":1},{"id":"2529389778","title":"Sanofi & Regeneron's Dupixent Receives FDA Nod for Urticaria","url":"https://stock-news.laohu8.com/highlight/detail?id=2529389778","media":"Zacks","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529389778?lang=en_us&edition=fundamental","pubTime":"2025-04-21 21:22","pubTimestamp":1745241720,"startTime":"0","endTime":"0","summary":"Sanofi SNY and partner Regeneron REGN announced that the FDA approved Dupixent  for the treatment of chronic spontaneous urticaria  in adults and adolescents aged 12 years and above, who remain symptomatic despite histamine-1  antihistamine treatment.Following the latest FDA nod, Dupixent became the first new targeted therapy to be approved for CSU in more than a decade. The drug is now approved for seven type II inflammatory diseases in the United States.Dupixent is already approved in several countries, including the United States and the European Union, for treating severe chronic rhinosinusitis with nasal polyposis, severe asthma, moderate-to-severe atopic dermatitis, eosinophilic esophagitis, prurigo nodularis and chronic obstructive pulmonary disease.CSU is an inflammatory skin condition, primarily occurring due to type 2 inflammation. This causes sudden and debilitating hives and swelling on the skin, which is mostly inadequately controlled by antihistamine treatment.Year to dat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sanofi-regenerons-dupixent-receives-fda-132200561.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","LU2362540622.SGD","LU0823416689.USD","BK4585","IE00BFXG1179.USD","LU1917777945.USD","IE00BN0W2W23.USD","LU1974910355.USD","BK4007","LU2362541513.USD","LU0114720955.EUR","BK4588","JAZZ","BK4533","IE00BN0W2V16.EUR","REGN","LU0889565916.HKD","LU0053666078.USD","LU2106854487.HKD","LU0882574055.USD","LU2468319806.SGD","LU2023250504.SGD","LU2362541273.HKD","BK4532","IE00BN0W2T93.GBP","SNYNF","LU0058720904.USD","KRYS","LU0109394709.USD","SNY","LU2237438978.USD","LU2089984988.USD","LU0289739699.SGD","LU0320765992.SGD"],"gpt_icon":0},{"id":"2529017098","title":"Apple may have a key problem bringing back manufacturing to beat Trump tariffs, former Intel CEO warns","url":"https://stock-news.laohu8.com/highlight/detail?id=2529017098","media":"Yahoo Finance","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529017098?lang=en_us&edition=fundamental","pubTime":"2025-04-21 21:21","pubTimestamp":1745241711,"startTime":"0","endTime":"0","summary":"Listen and subscribe to Opening Bid on Apple Podcasts, Spotify, Amazon Music, YouTube or wherever you find your favorite podcasts.Apple  won't be able to flip a switch overnight and begin making iPhones in the US to appease the Trump administration.Plus, moving the supply chain will come at a cost to consumers.\"What happens is you start to build on a certain place, and then the plastics company is built near where they are, and then the resistor company, and then the display company. And so what happens is these other elements of the supply chains start to aggregate around the core elements of the supply chain, so they sediment into those locations. And that sedimentation takes decades,\" former Intel  CEO Pat Gelsinger told me on Yahoo Finance's Opening Bid podcast .He added, \"There will be cost associated with bringing supply chains back. It took decades for them to sediment away. They don't return because you ask them to. They return because you've created economic incentives, capita","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/apple-may-have-a-key-problem-bringing-back-manufacturing-to-beat-trump-tariffs-former-intel-ceo-warns-132151346.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE0034235303.USD","LU0957808578.USD","LU1301847155.USD","LU2168563687.JPY","IE0005OL40V9.USD","SG9999000418.SGD","BK4512","LU2357305700.SGD","IE00BWXC8680.SGD","LU2097344357.USD","LU1116320901.HKD","LU1037948541.HKD","LU1244550221.USD","AAPL","LU2168564065.EUR","LU2106854487.HKD","LU0708995401.HKD","LU1582986359.USD","LU0234570918.USD","LU0784385170.HKD","IE0004445015.USD","IE00B5949003.HKD","BK4532","IE00BBT3K403.USD","LU0957791311.USD","LU2065171402.SGD","LU2471134952.CNY","LU0466842654.USD","LU0943347566.SGD","NVDA","MACW.SI","LU0215105999.USD","LU2592432038.USD","BK4559","BK4579","BK4598","IE00B4YYXB79.USD","INTC","LU0080751232.USD","LU2471134796.USD","LU2505996509.AUD","LU2750360641.GBP","SG9999018865.SGD","LU0234572021.USD","LU0265550946.USD","LU2417539215.USD","LU1935043536.SGD","AMD","LU0096364046.USD","LU2108987350.USD","LU0053666078.USD","LU0784383803.USD"],"gpt_icon":1},{"id":"2529801463","title":"Notable open interest changes for April 21st","url":"https://stock-news.laohu8.com/highlight/detail?id=2529801463","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529801463?lang=en_us&edition=fundamental","pubTime":"2025-04-21 21:01","pubTimestamp":1745240479,"startTime":"0","endTime":"0","summary":"Thursday’s total option volume of 57.3 million contracts resulted in net open interest growth of 7.79 million calls and 6.15 million puts. NVIDIA (...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/notable-open-interest-changes-for-april-21st-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/notable-open-interest-changes-for-april-21st-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVDU","LU0096364046.USD","IE00BQXX3D17.EUR","2NVD.UK","LU2491049909.HKD","LU0256863811.USD","LU0787776722.HKD","LU2191332357.HKD","LU0823414551.USD","LU2294711713.HKD","NVIW.SI","LU0029864427.USD","NVDA","LU1116320737.USD","NVDD","LU2290526834.HKD","LU1935042488.USD","LU2125909759.SGD","LU0985320562.USD","NVD3.UK","LU2125154935.USD","NVD2.UK","LU1868837300.USD","LU0061474960.USD","LU0345770993.USD","LU2430703251.USD","LU0494093205.USD","SNVD.UK","IE00BZ1G4Q59.USD","LU0107464264.USD","LU0289960550.SGD","LU1951198990.SGD","LU2065171402.SGD","NVDY","LU1084165304.USD","LU2237438978.USD","NVDS","BK4532","LU2430703095.HKD","NVDS.UK","LU0094547139.USD","3NVD.UK","LU0889565833.HKD","LU1868836757.USD","LU2211815571.USD","LU0965509010.AUD","HK0000320223.HKD"],"gpt_icon":0},{"id":"2529000618","title":"Why Investors Need to Take Advantage of These 2 Medical Stocks Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2529000618","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529000618?lang=en_us&edition=fundamental","pubTime":"2025-04-21 21:00","pubTimestamp":1745240408,"startTime":"0","endTime":"0","summary":"Quarterly financial reports play a vital role on Wall Street, as they help investors see how a company has performed and what might be coming down the road in the near-term. And out of all of the metrics and results to consider, earnings is one of the most important.We know earnings results are vital, but how a company performs compared to bottom line expectations can be even more important when it comes to stock prices, especially in the near-term. This means that investors might want to take advantage of these earnings surprises.The last thing we will do today, now that we have a grasp on the ESP and how powerful of a tool it can be, is to look at a qualifying stock. CVS Health  holds a Zacks Rank #3 at the moment and its Most Accurate Estimate comes in at $1.68 a share 10 days away from its upcoming earnings release on May 1, 2025.CVS is one of just a large database of Medical stocks with positive ESPs. Another solid-looking stock is Gilead Sciences .This article originally publishe","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-investors-advantage-2-medical-130008567.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0234570918.USD","LU0889565916.HKD","IE00BZ1G4Q59.USD","LU0061475181.USD","BK4581","GILD","LU0072461881.USD","BK4568","LU1066053197.SGD","LU0162691827.USD","LU1585245621.USD","ISBC","IE00B19Z3581.USD","LU0211331839.USD","LU2468319806.SGD","LU0058720904.USD","IE00BKVL7J92.USD","LU1571399168.USD","LU1699723380.USD","IE00B19Z3B42.SGD","BK4196","LU0320765992.SGD","BK4504","BK4139","IE00B3T34201.USD","LU0109394709.USD","BK4583","LU0006061336.USD","LU0070302665.USD","LU1066051498.USD","BK4211","LU2087621335.USD","BK4532","CVS","BK4550","LU0208291251.USD","IE0002270589.USD","LU1059921491.USD","BK4588","LU0289739699.SGD","BK4566","LU0320765489.SGD","BK4578","LU2089984988.USD","BK4585","IE00B7SZLL34.SGD","IE00BSNM7G36.USD","LU1430594728.SGD","LU1839511570.USD"],"gpt_icon":0},{"id":"2529093688","title":"Tariffs Weigh on Investor Sentiment, Driving Premarket Losses for US Equity Futures","url":"https://stock-news.laohu8.com/highlight/detail?id=2529093688","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529093688?lang=en_us&edition=fundamental","pubTime":"2025-04-21 20:58","pubTimestamp":1745240324,"startTime":"0","endTime":"0","summary":"US equity futures fell ahead of Monday's opening bell as investors digested developments surrounding the global tariff situation.Dow Jones Industrial Average futures were down 0.8%, S&P 500 futures fell 1.1%, and Nasdaq futures were 1.4% lower.China's commerce ministry warned it will take countermeasures against countries negotiating with the US at its expense.Oil prices were lower, with front-month global benchmark North Sea Brent crude down 2.4% at $66.36 per barrel and US West Texas Intermediate crude 2.6% lower at $62.38 per barrel.Forecasters see a 0.5% fall in the index of leading economic indicators for March, slated for 10 am ET, after a 0.3% decline in February, according to estimates compiled by Bloomberg.In other world markets, Japan's Nikkei ended 1.3% lower, and China's Shanghai Composite finished 0.5% higher. Markets in Hong Kong, the UK, and Germany were were closed for a holiday.In equities, shares of Netflix  were 2% higher pre-bell after the company reported late Thur","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0868494617.USD","BK4532","LU1548497426.USD","SGXZ23171101.USD","PSQ","LU0642271901.SGD",".IXIC","DOG","IE00B19Z9505.USD","IE00BQXX3F31.USD","NQmain","UDOW","LU0417517546.SGD","BK4099","LU0079474960.USD","USAW.SI","BK4516","TSYW.SI","DJX","QLD","LU0097036916.USD","EQR","LU1046421795.USD","F",".SPX","LU1823568750.SGD","LU2362541273.HKD","SQQQ","LU1720051017.SGD","BK4548","USJW.SI","QID","SDOW","DXD","LU1720051108.HKD","TQQQ","LU0868494708.USD","IE00BQXX3D17.EUR","LU0006306889.USD","LU0672654240.SGD","MNQmain",".DJI","DDM","NVIW.SI","BK4507","BK4527","BK4598"],"gpt_icon":1},{"id":"2529138887","title":"LLY Stock Up as Oral GLP-1 Pill Meets Goals in First Phase III Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2529138887","media":"Zacks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529138887?lang=en_us&edition=fundamental","pubTime":"2025-04-21 20:37","pubTimestamp":1745239020,"startTime":"0","endTime":"0","summary":"Shares of Eli Lilly LLY soared 14.3% on April 17 after data from a late-stage study showed that orforglipron achieved the primary goal of significantly reducing A1C levels compared to placebo at 40 weeks, with an average A1C reduction of 1.3% to 1.6% from a baseline of 8%. LLY’s orforglipron is an investigational, once-daily small-molecule oral GLP-1 receptor agonist that can be administered at any time of the day without restrictions on food and water intake.The phase III ACHIEVE-1 study, the first of sevenlate-stage studies, is evaluating the safety and efficacy of orforglipron compared to placebo in adults with type 2 diabetes  and inadequate glycemic control with diet and exercise alone. The enrolled patients in the 40-week study were randomized equally to receive either a 3 mg, 12 mg or 36 mg dose of orforglipron or placebo. Lilly is also developing a version of this oral drug for obesity.Year to date, shares of Lilly have gained 8.8% against the industry’s 3.3% decline.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lly-stock-oral-glp-1-123700472.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4532","LU0640476718.USD","LU1035775433.USD","LU1093756325.SGD","LU2089984988.USD","LLY","LU0354030511.USD","LU2360106947.USD","LU0256863811.USD","IE00B2B36J28.USD","LU0456855351.SGD","LU0094547139.USD","LU1023059063.AUD","LU1868836757.USD","LU2361044949.HKD","LU1366192091.USD","LU1868837300.USD","LU1720051108.HKD","SG9999018865.SGD","IE00BK4W5L77.USD","GPCR","BK4581","IE0004445239.USD","LU0238689110.USD","LU1712237335.SGD","SG9999017495.SGD","LU0114720955.EUR","LU1720051017.SGD","LU1548497426.USD","IE00BZ1G4Q59.USD","LU2237443382.USD","LU1061106388.HKD","GLP","LU0417517546.SGD","LU0096364046.USD","VKTX","LU2237443465.HKD","BK4534","LU0471298777.SGD","LU2471134952.CNY","LU0943347566.SGD","LU1093756168.USD","LU2237443622.USD","NVO","LU2264538146.SGD","LU2106854487.HKD","LU2324357040.USD","LU1551013342.USD","III","LU1280957306.USD"],"gpt_icon":1},{"id":"2529806872","title":"BRIEF-Gilead Reports Positive Topline Results From Phase 3 Ascent-04/Keynote-D19 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2529806872","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529806872?lang=en_us&edition=fundamental","pubTime":"2025-04-21 20:30","pubTimestamp":1745238609,"startTime":"0","endTime":"0","summary":"BRIEF-Gilead Reports Positive Topline Results From Phase 3 Ascent-04/Keynote-D19 StudyApril 21  - Gilead Sciences Inc GILD.O:TRODELVY PLUS KEYTRUDA DEMONSTRATES A STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENT IN PROGRESSION FREE SURVIVAL IN PATIENTS WITH PREVIOUSLY UNTREATED PD-L1+ METASTATIC TRIPLE-NEGATIVE BREAST CANCERGILEAD: POSITIVE TOPLINE RESULTS FROM PHASE 3 ASCENT-04/KEYNOTE-D19 STUDYGILEAD: STUDY SHOWED SUPERIORITY OF TRODELVY PLUS KEYTRUDA VERSUS STANDARD OF CARE  IN 1L METASTATIC TRIPLE-NEGATIVE BREAST CANCER GILEAD: STUDY MET MAIN GOAL, WITH STATISTICALLY SIGNIFICANT,CLINICALLY MEANINGFUL IMPROVEMENT IN PFSGILEAD: OVERALL SURVIVAL , KEY SECONDARY ENDPOINT, WASN'T MATURE AT TIME OF PFS PRIMARY ANALYSISGILEAD: TRODELVY PLUS KEYTRUDA SHOWS EARLY TREND IN IMPROVEMENT FOR OS VERSUS SOC IN PATIENTS WITH PREVIOUSLY UNTREATED PD-L1+  MTNBCGILEAD: WILL CONTINUE TO MONITOR OS OUTCOMESFurther company coverage: GILD.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250421:nP8N3K10U9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1699723380.USD","LU1989771016.USD","SG9999002224.SGD","LU1929549753.HKD","LU1989772840.SGD","LU0109394709.USD","LU0265550946.USD","LU0861579265.USD","LU0889565916.HKD","LU1037948897.HKD","LU1116320737.USD","MRK","BK4588","LU0058720904.USD","LU1057294990.SGD","LU1917777945.USD","BK4533","SG9999015358.SGD","LU2461242641.AUD","GILD","LU0965508806.USD","LU2468319806.SGD","LU0289739699.SGD","LU1934455194.USD","IE0002141913.USD","LU0320765489.SGD","IE0009355771.USD","LU1983299246.USD","LU0070302665.USD","BK4007","IE00B4R5TH58.HKD","BK4532","LU0320765992.SGD","LU1035773651.USD","SG9999001440.SGD","LU1291159041.SGD","BK4568","LU1066051225.USD","IE00BLSP4239.USD","IE00BN8TJ469.HKD","IE00BZ1G4Q59.USD","LU2089984988.USD","LU0234570918.USD","LU1023059063.AUD","LU1934455277.USD","BK4516","IE00BSNM7G36.USD","LU0203345920.USD","BK4534","LU0965509283.SGD"],"gpt_icon":1},{"id":"2529805192","title":"Gilead: Positive Topline Results From Phase 3 Ascent-04/Keynote-D19 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2529805192","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529805192?lang=en_us&edition=fundamental","pubTime":"2025-04-21 20:30","pubTimestamp":1745238603,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250421:nP8N3K10U9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4583","BK4585","LU0889565916.HKD","LU1839511570.USD","LU0320765992.SGD","GILD","LU0109394709.USD","BK4568","IE00B3T34201.USD","LU1430594728.SGD","LU1571399168.USD","LU0058720904.USD","IE00B7SZLL34.SGD","LU0234570918.USD","BK4532","IE00BKVL7J92.USD","LU1066053197.SGD","LU2468319806.SGD","BK4578","IE00B19Z3B42.SGD","IE0002270589.USD","IE00BSNM7G36.USD","IE00BZ1G4Q59.USD","LU0289739699.SGD","IE00B19Z3581.USD","BK4550","LU2087621335.USD","LU2089984988.USD","BK4588","BK4139","LU1066051498.USD","LU1585245621.USD","BK4566"],"gpt_icon":0},{"id":"2529805167","title":"Gilead: Overall Survival (Os), Key Secondary Endpoint, Wasn't Mature at Time of Pfs Primary Analysis","url":"https://stock-news.laohu8.com/highlight/detail?id=2529805167","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529805167?lang=en_us&edition=fundamental","pubTime":"2025-04-21 20:30","pubTimestamp":1745238603,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250421:nP8N3K10U9:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GILD","LU2089984988.USD","BK4568","BK4139","LU1571399168.USD","LU2468319806.SGD","IE00B19Z3581.USD","LU0058720904.USD","LU1839511570.USD","LU0109394709.USD","LU2087621335.USD","LU0289739699.SGD","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","IE00BSNM7G36.USD","IE00B19Z3B42.SGD","BK4566","IE00B7SZLL34.SGD","LU0889565916.HKD","LU1430594728.SGD","BK4588","BK4585","IE0002270589.USD","LU0320765992.SGD","LU0234570918.USD","IE00B3T34201.USD","LU1066053197.SGD","LU1585245621.USD","LU1066051498.USD","BK4583","BK4532","BK4550","BK4578"],"gpt_icon":0}],"pageSize":20,"totalPage":69,"pageCount":4,"totalSize":1372,"code":"91000000","status":"200"}]}}